DOCSLIB.ORG

SURGAM 300 Mg Tablets

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SURGAM 300 Mg Tablets Pays Laboratoires par modifié le par le créé Version N° Version Grande-Bretagne Sanofi DERIGNY C 13/07/2021 DERIGNY C 15/10/2020 Package leaet: Information for the user ³ You are allergic (hypersensitive) to any 1. What SURGAM is and what it other similar medicines (non-steroidal anti- SURGAM 300 mg Tablets is used for inflammatory drugs or NSAIDs) such as aspirin The name of your medicine is SURGAM or ibuprofen. 6 tiaprofenic acid 300 mg Tablets (called SURGAM in this leaflet). ³ You have or ever had an ulcer (burning, aching SURGAM contains a medicine called tiaprofenic pain with an empty feeling and hunger) or Type ArticleType acid. This belongs to a group of medicines called bleeding in your stomach or gut. Quantité Dosage Référence article Nom duproduit ‘non-steroidal anti- inflammatory drugs’ (NSAIDs). ³ You have or ever had asthma. Is this leaflet hard to It works by blocking some chemicals in your body ³ You have severe heart problems. see or read? that normally cause inflammation. ³ You have kidney or liver problems. Nbre/Réf. Couleur It is used to treat the swelling, pain, heat, redness ³ You have or ever had problems passing water Phone 0800 035 2525 and stiffness in your joints and muscles in the (urine) such as pain, blood in your urine or following: passing water more often than usual. for help ³ cprs 300 mg R789740 Surgam Notice double You are in the last three months of pregnancy • Rheumatoid arthritis (inflammation of the 1 (see ‘pregnancy and breast-feeding’ below). Read all of this leaflet carefully before joints) Zone d’implantationdestextes. • Osteoarthritis (where the cushioning (cartilage) Do not take this medicine if any of the above you start taking this medicine because it BlueU Bleu Reflex between the bone joints is damaged) apply to you. If you are not sure, talk to your contains important information for you. • Lower back pain doctor or pharmacist before taking SURGAM. • Keep this leaflet. You may need to read it again. 2 • Sprains and strains Text area. • If you have any further questions, ask your Warnings and precautions Page • Pain1 and inflammation after an operation Talk to your doctor or pharmacist before doctor or pharmacist. • Other painful inflammatory joint or muscle 3 taking SURGAM if: • This medicine has been prescribed for you only. problems Do not1 pass it on to others. It may harm them, 4 c You often have or ever had something called even if their signs of illness are the same as minicaractères Taille Dimensions N° planpositionnement N° planDimensionnel N° version Country Ex. N° version Logo/Name 2. What you need to know before you ‘rhinitis’ (runny nose, itching, sneezing and stuffy yours. take SURGAM nose – for example if you have hayfever). • If you get any side effects, talk to your doctor c You often have or ever had something called or pharmacist. This includes any possible side ‘urticaria’ (itchy lumpy rash). effects not listed in this leaflet. See section 4. Do not take this medicine and tell c You have ulcerative colitis or Crohn’s disease. What is in this leaflet: your doctor if: c You have a disease affecting the skin, joints or 1. What SURGAM is and what it is used for kidney called ‘Sytemic Lupus Erythematous’ (SLE). ³ 2. What you need to know before you take You are allergic to tiaprofenic acid or any of c You are elderly. the other ingredients of this medicine listed SURGAM c You have blood problems (such as unusual 3. How to take SURGAM in section 6. bruising or bleeding). 9 pts 150 x210mm 606062-1d 1-606062 -V105/2012 CRGB N.A. ³ 4. Possible side effects Signs of an allergic reaction include: a rash, c You have ever had high blood pressure 5. How to store SURGAM swallowing or breathing problems, swelling of (hypertension). 6. Contents of the pack and other information your lips, face, throat or tongue. c You have ever had heart problems such as a stroke. - 1 - R789740 Numéro depages Code sécurité R789740 1/4 Pays Laboratoires par modifié le par le créé Version N° Version Grande-Bretagne Sanofi DERIGNY C 13/07/2021 DERIGNY C 15/10/2020 c You have diabetes. Also some medicines can affect the way SURGAM works. • Probenecid - used with a medicine called c You have ever had a high cholesterol level. In particular, tell your doctor if you are taking any cidofovir to stop kidney damage c You are a smoker. of the following: • Tacrolimus - used after an organ transplant c You think you might be at risk of heart problems • Other non-steroidal anti-inflammatory drugs • Zidovudine - an antiretroviral drug 6 such as stroke. such as aspirin, ibuprofen, celecoxib, etodolac • Nicorandil - used for treating chest pain c You are having or have had heart bypass surgery. or meloxicam Please tell your doctor if you are taking any of Type ArticleType c You are in the first six months of pregnancy (see • Water tablets (diuretics) such as spironolactone, these medicines. Quantité Dosage Référence article Nom duproduit ‘pregnancy and breast-feeding’ below). triamterene or amiloride used to increase the Pregnancy and breast-feeding c You are planning to become pregnant or you flow of your water (urine) Talk to your doctor before taking this medicine if: Nbre/Réf. Couleur have problems becoming pregnant. SURGAM • Antibiotics such as quinolone, sulphonamides • You are pregnant, might become pregnant, or may make it more difficult to become pregnant. or aminoglycosides (for infections) think you may be pregnant c You have an infection – please see heading • Corticosteroids such as prednisolone (for • You are breast-feeding or planning to breast- inflammation, allergies or some types of cancer) “Infections” below. Zone d’implantationdestextes. feed cprs 300 mg R789740 Surgam Notice double • Medicines for lowering your blood sugar such 1 Infections Ask your doctor or pharmacist for advice before as medicines for diabetes SURGAM may hide signs and symptoms of taking any medicine if you are pregnant or breast- • Medicines for lowering your blood pressure BlueU Bleu Reflex infections such as fever and pain. It is therefore feeding. 2 (antihypertensives) Text area. possible that SURGAM may delay appropriate • Medicines called ‘cardiac glycosides’ such as Driving and using machines 1 treatmentPage of infection, which may lead to an digoxin (for heart failure) You may feel sleepy, dizzy, faint or your increased risk of complications. This has been • Medicine to 3 stop your blood clotting such as eyesight may be affected while taking this observed in pneumonia caused by bacteria and medicine. If this happens, do not drive or 2 heparin,4 warfarin, clopidogrel, ticlopidine, bacterial skin infections related to chickenpox. dabigatran, apixaban, rivaroxaban or edoxaban use any tools or machines. If you take this medicine while you have an • Medicine to dissolve blood clots such as 3. How to take SURGAM infection and your symptoms of the infection minicaractères Taille Dimensions N° planpositionnement N° planDimensionnel N° version Country Ex. N° version Logo/Name streptokinase, alteplase, reteplase or tenecteplase persist or worsen, consult a doctor without delay. • Pentoxifylline - used to increase blood flow to Always take this medicine exactly as your doctor Children and adolescents arms and legs. has told you. You should check with your doctor SURGAM is not recommended for use in children • Ciclosporin – used after an organ transplantation or pharmacist if you are not sure. and adolescents because their safety and efficacy to help prevent rejection Taking this medicine has not yet been established. • Medicines for depression such as fluoxetine, If you are not sure if any of the above apply to you, • Take this medicine by mouth sertraline, citalopram or paroxetine • Take with or after food talk to your doctor or pharmacist before taking • Mifepristone - for terminating a pregnancy. It is SURGAM. • Swallow the tablets whole with a drink of water important not to use SURGAM for at least 8–12 • Do not crush or chew your tablets Other medicines and SURGAM 9 pts 150 x210mm 606062-1d 1-606062 -V105/2012 CRGB N.A. days after taking Mifepristone • If you feel the effect of your medicine is too Tell your doctor or pharmacist if you • Lithium - for some types of mental illness are taking, have recently taken or might weak or too strong, do not change the dose • Phenytoin - for epilepsy yourself, but ask your doctor take any other medicines. This is because • Methotrexate - for some types of cancer SURGAM can affect the way some other • Tenofovir – an antiretroviral medicine which is Adults medicines work. used to treat HIV infection The usual dose of SURGAM is 1 tablet twice a day. - 2 - Numéro depages 2/4 Code sécurité R789740 Pays Laboratoires par modifié le par le créé Version N° Version Grande-Bretagne Sanofi DERIGNY C 13/07/2021 DERIGNY C 15/10/2020 Children Stop taking and see your doctor or go to a • You feel pain when passing water (urine), have SURGAM is not recommended for children. hospital straight away if: to pass water more often than usual, have 6 The elderly (over 65 years) • You have an allergic reaction. The signs may blood in your urine as you may have swelling You are more likely to get side effects while taking include: a rash, swallowing or breathing problems, of the bladder SURGAM. Your doctor may lower the number of swelling of your lips, face, throat or tongue • Your limbs are swollen (signs of fluid retention), ArticleType tablets that you take. • You have difficulty breathing, wheezing, tightness you feel tired (fatigued) and generally unwell. You Quantité Dosage Référence article Nom duproduit If you take more SURGAM than you should in the chest (something called ‘bronchospasm’) may have kidney problems which, if untreated, If you take more tablets than you should, tell a • Your asthma is getting worse - this may be a could become very serious.
Load more

Recommended publications
  • Nsaids: Dare to Compare 1997
    NSAIDs TheRxFiles DARE TO COMPARE Produced by the Community Drug Utilization Program, a Saskatoon District Health/St. Paul's Hospital program July 1997 funded by Saskatchewan Health. For more information check v our website www.sdh.sk.ca/RxFiles or, contact Loren Regier C/O Pharmacy Department, Saskatoon City Hospital, 701 Queen St. Saskatoon, SK S7K 0M7, Ph (306)655-8506, Fax (306)655-8804; Email [email protected] We have come a long way from the days of willow Highlights bark. Today salicylates and non-steroidal anti- • All NSAIDs have similar efficacy and side inflammatory drugs (NSAIDs) comprise one of the effect profiles largest and most commonly prescribed groups of • In low risk patients, Ibuprofen and naproxen drugs worldwide.1 In Saskatchewan, over 20 may be first choice agents because they are different agents are available, accounting for more effective, well tolerated and inexpensive than 300,000 prescriptions and over $7 million in • Acetaminophen is the recommended first line sales each year (Saskatchewan Health-Drug Plan agent for osteoarthritis data 1996). Despite the wide selection, NSAIDs • are more alike than different. Although they do Misoprostol is the only approved agent for differ in chemical structure, pharmacokinetics, and prophylaxis of NSAID-induced ulcers and is to some degree pharmacodynamics, they share recommended in high risk patients if NSAIDS similar mechanisms of action, efficacy, and adverse cannot be avoided. effects. week or more to become established. For this EFFICACY reason, an adequate trial of 1-2 weeks should be NSAIDs work by inhibiting cyclooxygenase (COX) allowed before increasing the dose or changing to and subsequent prostaglandin synthesis as well as another NSAID.
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH NOVO–KETOROLAC (ketorolac tromethamine) 10 mg Tablets NSAID Analgesic Agent Novopharm Limited Date of Revision: Toronto, Canada August 02, 2007 Control Number 112565 PRODUCT MONOGRAPH NOVO–KETOROLAC (ketorolac tromethamine) 10 mg Tablets THERAPEUTIC CLASSIFICATION NSAID Analgesic Agent ACTION AND CLINICAL PHARMACOLOGY NOVO-KETOROLAC (ketorolac tromethamine) is a non-steroidal anti-inflammatory drug (NSAID) that has analgesic activity. It is considered to be a peripherally acting analgesic. It is thought to inhibit the cyclo-oxygenase enzyme system, thereby inhibiting the synthesis of prostaglandins. At analgesic doses it has minimal anti-inflammatory and antipyretic activity. The peak analgesic effect occurs at 2 to 3 hours post-dosing with no evidence of a statistically significant difference over the recommended dosage range. The greatest difference between large and small doses of administered ketorolac is in the duration of analgesia. Following oral administration, ketorolac tromethamine is rapidly and completely absorbed, and pharmacokinetics are linear following single and multiple dosing. Steady state plasma levels are achieved after one day of q.i.d. dosing. - 2 - Peak plasma concentrations of 0.7 to 1.1 µg/mL occurred at 44 minutes following a single oral dose of 10 mg. The terminal plasma elimination half-life ranged between 2.4 and 9 hours in healthy adults, while in the elderly subjects (mean age: 72 years) it ranged between 4.3 and 7.6 hours. A high fat meal decreased the rate but not the extent of absorption of oral ketorolac tromethamine, while antacid had no effect. In renally impaired patients there is a reduction in clearance and an increase in the terminal half- life of ketorolac tromethamine (See Table 1).
    [Show full text]
  • Of 20 PRODUCT MONOGRAPH FLURBIPROFEN Flurbiprofen Tablets BP 50 Mg and 100 Mg Anti-Inflammatory, Analgesic Agent AA PHARM
    PRODUCT MONOGRAPH FLURBIPROFEN Flurbiprofen Tablets BP 50 mg and 100 mg Anti-inflammatory, analgesic agent AA PHARMA INC. DATE OF PREPARATION: 1165 Creditstone Road, Unit #1 April 16, 1991 Vaughan, Ontario L4K 4N7 DATE OF REVISION: February 7, 2019 Submission Control No. 223098 Page 1 of 20 PRODUCT MONOGRAPH NAME OF DRUG FLURBIPROFEN Flurbiprofen Tablets BP 50 mg and 100 mg PHARMACOLOGICAL CLASSIFICATION Anti-inflammatory, analgesic agent ACTIONS AND CLINICAL PHARMACOLOGY FLURBIPROFEN (flurbiprofen), a phenylalkanoic acid derivative, is a non-steroidal anti- inflammatory agent which also possesses analgesic and antipyretic activities. Its mode of action, like that of other non-steroidal anti-inflammatory agents, is not known. However, its therapeutic action is not due to pituitary adrenal stimulation. Flurbiprofen is an inhibitor of prostaglandin synthesis. The resulting decrease in prostaglandin synthesis may partially explain the drug's anti-inflammatory effect at the cellular level. Pharmacokinetics: Flurbiprofen is well absorbed after oral administration, reaching peak blood levels in approximately 1.5 hours (range 0.5 to 4 hours). Administration of flurbiprofen with food does not alter total drug availability but delays absorption. Excretion of flurbiprofen is virtually complete 24 hours after the last dose. The elimination half-life is 5.7 hours with 90% of the half-life values from 3-9 hours. There is no evidence of drug accumulation and flurbiprofen does not induce enzymes that alter its metabolism. Flurbiprofen is rapidly metabolized and excreted in the urine as free and unaltered intact drug (20-25%) and hydroxylated metabolites (60-80%). In animal models of inflammation the metabolites showed no activity.
    [Show full text]
  • Patient Information Leaflet: Information for the User <Invented Name> 30
    Patient Information Leaflet: Information for the user <Invented name> 30 mg/ml solution for injection ketorolac trometamol Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or nurse. • If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What <Invented name> is and what it is used for 2. What you need to know before you are given <Invented name> 3. How <Invented name> is given 4. Possible side effects 5. How to store <Invented name> 6. Contents of the pack and other information 1. What <Invented name> is and what it is used for <Invented name> contains an active substance called ketorolac trometamol and belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). Ketorolac is used in hospital, for short-term relief of moderate to severe pain after operations and in the case of acute kidney stone pain, in adults and adolescents ≥16 years. 2. What you need to know before you are given <Invented name> <Invented name> should not be used before or during surgery due to increased risk of bleeding. <Invented name> must not be given by epidural or intrathecal administration . Severe anaphylactic-like reactions have been observed in patients with a history of allergic reactions (symptoms of asthma, inflammation of the nasal mucosa or skin reactions) to the use of acetylsalicylic acid (e.g.
    [Show full text]
  • 2 Inhibitors and Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
    Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs) Final Report Update 3 Evidence Tables November 2006 Original Report Date: May 2002 Update 1 Report Date: September 2003 Update 2 Report Date: May 2004 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Roger Chou, MD Mark Helfand, MD, MPH Kim Peterson, MS Tracy Dana, MLS Carol Roberts, BS Produced by Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, Director Copyright © 2006 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Note: A scan of the medical literature relating to the topic is done periodically(see http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report. Some portions of the report may not be up to date. Prior versions of this report can be accessed at the DERP website. Final Report Update 3 Drug Effectiveness Review Project TABLE OF CONTENTS Evidence Table 1. Systematic reviews…………………………………………………………………3 Evidence Table 2. Randomized-controlled trials………………………………………………………9 Evidence Table 3.
    [Show full text]
  • Annrheumd00427-0020.Pdf
    Annals of the Rheumatic Diseases, 1989; 48, 372-381 Evaluation of the effects of antiarthritic drugs on the secretion of proteoglycans by lapine chondrocytes using a novel assay procedure SIMON COLLIER AND PETER GHOSH From the Raymond Purves Research Laboratories (The University of Sydney) at the Royal North Shore Hospital of Sydney, St Leonards, NSW 2065, Australia SUMMARY A new method is described for separating free 35SO4- from 35SO4 labelled groteoglycans synthesised by rabbit articular chondrocytes cultured in the presence of excess 4 The procedure uses the low solubility product of barium sulphate to remove, by precipitation, free 35SO4- from culture medium. Optimum recovery of 35so4 labelled proteoglycans was achieved after papain digestion to release 35SO4-glycosaminoglycans, and addition of chondroitin sulphate before the precipitation step. Using this assay, we studied the effect of six drugs-indomethacin, diclofenac, sodium pentosan polysulphate, glycosaminoglycan polysulphate ester, tiaprofenic acid, and ketoprofen-on the secretion into the medium of labelled proteoglycans by lapine chondrocytes. The six drugs were tested at 0< 1, 1, 10, 50, and 100 I.g/ml over four consecutive 48 hour culture periods. A consistent concentration-response pattern was found for the four non-steroidal anti-inflammatory drugs (NSAIDs) studied. Generally they inhibited proteoglycan secretion at 50 and 100 [ig/ml but had no effect at lower concentrations. Inhibition of secretion was strongest with indomethacin and diclofenac at 50 and 100 ig/ml. In contrast with the NSAIDs studied, the two sulphated polysaccharides (sodium pentosan polysulphate and glycosaminoglycan polysulphate ester) at low concentrations increased proteoglycan secretion by chondrocytes, with maximal stimulation occurring at 1 [ig/ml.
    [Show full text]
  • Read This for Safe and Effective Use of Your Medicine
    PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE VIMOVO® naproxen/esomeprazole modified release tablets Read this carefully before you start taking VIMOVO and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about VIMOVO. Serious Warnings and Precautions If you have, or previously had, any of the following medical conditions, see your health care provider to discuss treatment options other than VIMOVO: • Heart Attack or Angina • Stroke or Mini-stroke • Loss of Vision • Current Pregnancy (less than 28 weeks) • Congestive Heart Failure What is VIMOVO used for? VIMOVO is used in adults to treat the signs and symptoms of: • Osteoarthritis • Rheumatoid arthritis • Ankylosing spondylitis VIMOVO helps to reduce pain, swelling, redness and heat (inflammation). It is used for people who: • need to take an anti-inflammatory medicine. • and are at risk of getting a stomach ulcer (sore) or an ulcer in the small intestine (gut). How does VIMOVO work? VIMOVO contains 2 drugs which work together. • Naproxen belongs to a group of medicines called “nonsteroidal anti-inflammatory drugs” (NSAIDs). It reduces the substances in your body which cause pain and swelling. • Esomeprazole belongs to a group of medicines called “proton pump inhibitors” (PPIs). It reduces the amount of acid produced by your stomach. • Naproxen can damage the stomach but esomeprazole helps reduce this damage. • VIMOVO only treats the symptoms of pain and inflammation of the illness as long as you use it.
    [Show full text]
  • Inflammatory Drugs (Nsaids) for People with Or at Risk of COVID-19
    Evidence review Acute use of non-steroidal anti- inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 Publication date: April 2020 This evidence review sets out the best available evidence on acute use of non- steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19. It should be read in conjunction with the evidence summary, which gives the key messages. Evidence review commissioned by NHS England Disclaimer The content of this evidence review was up-to-date on 24 March 2020. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. For details on the date the searches for evidence were conducted see the search strategy. Copyright © NICE 2020. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3763-9 Contents Contents ...................................................................................................... 1 Background ................................................................................................. 2 Intervention .................................................................................................. 2 Clinical problem ........................................................................................... 3 Objective ...................................................................................................... 3 Methodology ................................................................................................ 4 Summary of included studies
    [Show full text]
  • Cyclooxygenase
    COX Cyclooxygenase Cyclooxygenase (COX), officially known as prostaglandin-endoperoxide synthase (PTGS), is an enzyme that is responsible for formation of important biological mediators called prostanoids, including prostaglandins, prostacyclin and thromboxane. Pharmacological inhibition of COX can provide relief from the symptoms of inflammation and pain. Drugs, like Aspirin, that inhibit cyclooxygenase activity have been available to the public for about 100 years. Two cyclooxygenase isoforms have been identified and are referred to as COX-1 and COX-2. Under many circumstances the COX-1 enzyme is produced constitutively (i.e., gastric mucosa) whereas COX-2 is inducible (i.e., sites of inflammation). Non-steroidal anti-inflammatory drugs (NSAID), such as aspirin and ibuprofen, exert their effects through inhibition of COX. The main COX inhibitors are the non-steroidal anti-inflammatory drugs (NSAIDs). www.MedChemExpress.com 1 COX Inhibitors, Antagonists, Activators & Modulators (+)-Catechin hydrate (-)-Catechin Cat. No.: HY-N0355 ((-)-Cianidanol; (-)-Catechuic acid) Cat. No.: HY-N0898A (+)-Catechin hydrate inhibits cyclooxygenase-1 (-)-Catechin, isolated from green tea, is an (COX-1) with an IC50 of 1.4 μM. isomer of Catechin having a trans 2S,3R configuration at the chiral center. Catechin inhibits cyclooxygenase-1 (COX-1) with an IC50 of 1.4 μM. Purity: 99.59% Purity: 98.78% Clinical Data: Phase 4 Clinical Data: No Development Reported Size: 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg (-)-Catechin gallate (-)-Epicatechin ((-)-Catechin 3-gallate; (-)-Catechin 3-O-gallate) Cat. No.: HY-N0356 ((-)-Epicatechol; Epicatechin; epi-Catechin) Cat. No.: HY-N0001 (-)-Catechin gallate is a minor constituent in (-)-Epicatechin inhibits cyclooxygenase-1 (COX-1) green tea catechins.
    [Show full text]
  • Ketorolac Tromethamine Injection, USP
    PRODUCT MONOGRAPH Pr Ketorolac Tromethamine Injection, USP 30 mg / mL single-dose vials 30 mg / mL in SimplistTM prefilled single use syringes For Intramuscular Administration Non-Steroidal Anti-Inflammatory Analgesic Agent Fresenius Kabi Canada Ltd. Date of Revision: 165 Galaxy Blvd, Suite 100 July 18, 2019 Toronto, ON M9W 0C8 Submission Control No.: 227928 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ................................................................................3 INDICATIONS AND CLINICAL USE .....................................................................................3 CONTRAINDICATIONS ...........................................................................................................4 WARNINGS AND PRECAUTIONS .........................................................................................5 ADVERSE REACTIONS .........................................................................................................14 DRUG INTERACTIONS..........................................................................................................16 DOSAGE AND ADMINISTRATION .....................................................................................18 OVERDOSAGE ........................................................................................................................22 ACTION AND CLINICAL PHARMACOLOGY ....................................................................23 STORAGE
    [Show full text]
  • Effects of Tiaprofenic Acid (Surgam) on Cartilage
    448 Annals ofthe Rheumatic Diseases 1992; 51: 448-455 Effects of tiaprofenic acid (Surgam) on cartilage proteoglycans in the rabbit joint immobilisation Ann Rheum Dis: first published as 10.1136/ard.51.4.448 on 1 April 1992. Downloaded from model Isabelle Meyer-Carrive, Peter Ghosh Abstract pressive deformation.4 5 Biochemical and histo- A well established model of arthritis induced chemical studies of cartilage from osteoarthritic in rabbit knee joints by immobilisation in full joints have shown that proteoglycans are lost extension for 30 days was used to evaluate the from the matrix in the more advanced stages of in vivo effects of 2-5, 5-0, and 10-0 mg/kg body the disease."8 The depletion of these macro- weight oftiaprofenic acid on articular cartilage molecules results in a decline in the resilience of proteoglycans. The drug was given sub- the tissue, and the mechanical stresses trans- cutaneously every 24 hours during the entire mitted across the joint may contribute to the immobilisation period. Immobilised animals progression of pathological changes in cartilage not treated with drugs and normal animals and subchondral bone. were used as controls. In the non-drug treated Non-steroidal anti-inflammatory drugs immobilised animals articular cartilage showed (NSAIDs) are extensively used in the manage- evidence of surface damage accompanied ment of osteoarthritis, but there is continuing by synovial hypertrophy and effusion. Proteo- debate about their beneficial or adverse effects glycan concentrations were reduced in on cartilage integrity."' Some laboratory and cartilages of these joints and the incorporation clinical evidence9 11-14 suggests that several of of 35SO24 into macromolecular proteoglycans the older NSAIDs may suppress the biosynthesis was higher than in cartilages of non-im- of proteoglycans in cartilage, thereby accel- mobilised controls.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of - Medicines belonging to the ATC group M01 (Antiinflammatory and antirheumatic products) Table of Contents Page INTRODUCTION 6 DISCLAIMER 8 GLOSSARY OF TERMS USED IN THIS DOCUMENT 9 ACTIVE SUBSTANCES Phenylbutazone (ATC: M01AA01) 11 Mofebutazone (ATC: M01AA02) 17 Oxyphenbutazone (ATC: M01AA03) 18 Clofezone (ATC: M01AA05) 19 Kebuzone (ATC: M01AA06) 20 Indometacin (ATC: M01AB01) 21 Sulindac (ATC: M01AB02) 25 Tolmetin (ATC: M01AB03) 30 Zomepirac (ATC: M01AB04) 33 Diclofenac (ATC: M01AB05) 34 Alclofenac (ATC: M01AB06) 39 Bumadizone (ATC: M01AB07) 40 Etodolac (ATC: M01AB08) 41 Lonazolac (ATC: M01AB09) 45 Fentiazac (ATC: M01AB10) 46 Acemetacin (ATC: M01AB11) 48 Difenpiramide (ATC: M01AB12) 53 Oxametacin (ATC: M01AB13) 54 Proglumetacin (ATC: M01AB14) 55 Ketorolac (ATC: M01AB15) 57 Aceclofenac (ATC: M01AB16) 63 Bufexamac (ATC: M01AB17) 67 2 Indometacin, Combinations (ATC: M01AB51) 68 Diclofenac, Combinations (ATC: M01AB55) 69 Piroxicam (ATC: M01AC01) 73 Tenoxicam (ATC: M01AC02) 77 Droxicam (ATC: M01AC04) 82 Lornoxicam (ATC: M01AC05) 83 Meloxicam (ATC: M01AC06) 87 Meloxicam, Combinations (ATC: M01AC56) 91 Ibuprofen (ATC: M01AE01) 92 Naproxen (ATC: M01AE02) 98 Ketoprofen (ATC: M01AE03) 104 Fenoprofen (ATC: M01AE04) 109 Fenbufen (ATC: M01AE05) 112 Benoxaprofen (ATC: M01AE06) 113 Suprofen (ATC: M01AE07) 114 Pirprofen (ATC: M01AE08) 115 Flurbiprofen (ATC: M01AE09) 116 Indoprofen (ATC: M01AE10) 120 Tiaprofenic Acid (ATC:
    [Show full text]